Loading...

Member Profile

Raypal Biomedical Co., Ltd. established in May 2016 devotes to researching of immune cell therapy for cancer and stem cell regenerative therapy based on the spirit of proactiveness, innovation and enthusiasm.

Our first phase I/II clinical trial “Evaluate the safety and efficacy of cytokine-induced killer treatment for advanced hepatocellular carcinoma patient” was approved by Ministry of Health and Welfare on March 2018. Furthermore, Ministry of Health and Welfare also has approved those plans which we applied for the specific cellular therapeutic technology of autologous CIK for stage IV solid tumor with many hospitals since February 2020. Currently, we are building the first GTP grade laboratory inside the southern medical center and planning to construct PIC/S GMP grade cell processing unit (CPU) at Neihu Technology Park in Taipei.

Raypal Biomedical will keep on developing the research of innovative anti-cancer therapies, promoting our potentiality for biomedical sciences as well as persevering in improving human health and quality of life.


Company Milestones

   2018 Phase I/II clinical trial, Evaluate the safety and efficacy of cytokine-induced killer treatment for advanced hepatocellular carcinoma patient” was approved by Ministry of Health and Welfare on March 2018.
   2020 Raypal Biomedical cooperated with Cheng Ching Hospital; the autologous CIK cells therapy plan for late-stage cancer was approved by MOHW.
   2020 Raypal Biomedical cooperated with Tungs’Taichung Metro Harbor Hospital; the autologous CIK cells therapy plan for late-stage cancer was approved by MOHW.
   2020 Raypal Biomedical cooperated with Kaohsiung Medical University Chung-Ho Memorial Hospital; the autologous CIK cells therapy plan for late-stage cancer was approved by MOHW.
   2020 Raypal Biomedical cooperated with Chi Mei Hospital; the autologous CIK cells therapy plan for late-stage cancer was approved by MOHW.